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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
L-carnitine decreases mortality rates post MI.
STUDY DESIGN: Review of three randomized controlled trials published in 1996, 2000,
and 2012, all English language.
DATA SOURCES: Three double blind, randomized controlled clinical trials comparing
mortality rates in patients post MI who were treated with L-carnitine or a placebo. All
articles were found using PubMed and EBSCO.
OUTCOMES MEASURED:
In the Singh et al. study the outcomes were total cardiac events that included death and
nonfatal infarctions, cardiac enzymes activity, infarct size, and any complications that
were measured by myocardial infarct size, cardiac enzyme levels of CK and CK-MB,
radiology, and electrocardiographic. In the Colonna study, outcomes were: left
ventricular dilation, end diastolic volume, systolic volume, incidence of death and heart
failure at 6 months, and infarct size that were measured by an echocardiograph. In the
Tarantini study, the outcomes measured were: combined occurrence of death and heart
failure that were measured by deaths.
RESULTS: In the Singh et al. study the total cardiac events including nonfatal infarction
and cardiac deaths were significantly fewer in the L-carnitine group compared to placebo
in 28 days. In the Tarantini study, a reduction in mortality was seen in the L-carnitine arm
of the study at 5 days. The	
  Colonna	
  study	
  results	
  shows	
  L-‐Carnitine	
  does	
  not	
  seem	
  to	
  
be	
  effective	
  in	
  reducing	
  mortality	
  in	
  patients	
  after	
  AMI.
CONCLUSIONS: The results of these RCTs suggest that L-carnitine isn’t much more
effective in reducing mortality rates after AMIs than the placebo. There	
  was	
  some	
  
evidence	
  to	
  suggest	
  that	
  L-‐carnitine	
  may	
  be	
  effective	
  in	
  reducing	
  mortality	
  short-‐
term	
  after	
  an	
  AMI	
  but	
  not	
  long	
  term.	
  	
  	
  The	
  studies	
  reviewed	
  demonstrated	
  
statistically	
  significant	
  decreases	
  in	
  mortality	
  only	
  in	
  the	
  time	
  frame	
  directly	
  
following	
  an	
  AMI.	
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INTRODUCTION

Myocardial infarction (MI or heart attack) occurs when blood flow is blocked to an area
of the heart muscle that causes ischemic damage or death to the myocardial cells. Myocardial
infarctions are potentially fatal conditions that are among the leading causes of death in both men
and women worldwide. Carnitine plays a critical role in energy production and is found in high
concentrations in cardiac muscle1. This paper evaluates three randomized controlled trials
(RCTs) comparing the efficacy of L-Carnitine in preventing mortality in patients post myocardial
infarction.
This topic/question is relevant to patients, doctors, and physician assistant practice
because it is common, costly and accounts for a significant amount of healthcare visits.
Prevalence of myocardial infarctions increase with age. It is estimated that 60-65% of MIs occur
in patients above 65 years old and 28-33% occur in patients above 75 years old. Eighty percent
of all deaths related to myocardial infarctions occur in persons above 65 years of age2. Coronary
heart diseases cost $108.9 billion each year in the US3. Coronary heart disease and myocardial
infarctions account for a significant amount of healthcare visits: in 2010, AHA reports that 17.6
million people in the United States have coronary heart disease with 8.5 million having
myocardial infarctions4.
Myocardial infarction is defined as a clinical (or pathologic) event caused by myocardial
ischemia in which there is evidence of myocardial injury or necrosis. Detection of a rise and fall
of cardiac biomarker values is a crucial criterion in the diagnosis of MIs. Additionally, at least
one of the following criteria are also needed to verify the diagnosis: symptoms of ischemia,
development of pathologic Q waves in the electrocardiography (ECG), new or presumed new
significant ST segment-T wave changes or new left bundle branch block (LBBB), identification
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of an intracoronary thrombus by angiography or autopsy, imaging evidence of new loss or viable
myocardium or a new regional wall motion abnormality4.
The usual methods of treatments of myocardial infarction and coronary artery disease are:
relief of ischemic pain and oxygen therapy, assessment of the hemodynamic state and correction
of abnormalities, initiation of reperfusion therapy with primary PCI or fibrinolysis,
antithrombotic therapy to prevent re-thrombosis or acute stent thrombosis, beta blocker therapy
to prevent recurrent ischemia and arrhythmias, Coronary Artery Bypass Graft (CABG), and
lifestyle modifications: diet, EtOH, smoking cessation, and weight loss2.
Carnitine is found in high concentrations in cardiac muscle and serves several important
physiological functions in the heart5. This method of treatment is being proposed to determine if
L-carnitine decreases infarct sizes because carnitine deficiency is more significant in the
infarcted portion of the myocardium than in healthy myocardium. Studies have shown
potentially beneficial effects with L-carnitine administration in improving clinical status and
survival of patients post myocardial infarctions4.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not L-carnitine
decreases mortality rates post myocardial infarction.
METHODS
The RCTs analyzed patients who had an acute myocardial infarction within 8-10 hours of
symptoms. The intervention studied in the RCTs was L-Carnitine. In the Singh et al. study,
patients were given 1.98g/d of L-Carintine6. In the Colonna et al. study, patients were given LCarnitine 9g/d continuous IV for the first 5 days, then PO 2g TID for next 12 months7. In the
Tarantini et al. study, patients were given L-carnitine 9g/d by continuous IV infusion for initial 5
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days then 4g/d orally for next 6 months8. In all three RCTs, treatment groups received LCarnitine compared to the experimental group who received a placebo at the same dosage
schedules. The following are measured outcomes that were utilized: total cardiac events
including death and nonfatal infarctions, cardiac enzymes activity, infarct size, and
complications (heart failure, and left ventricular dilation).
Key words used in the searches were “L-Carnitine” and “Myocardial Infarction”. All
articles were published in peer-reviewed journals in the English language. The articles were
selected through PubMed and EBSCO; the selected articles were based on relevance to the
clinical question and that the studies outcomes were patient oriented outcomes (POEMs).
Inclusion criteria consisted of: patients who were judged to likely have an acute myocardial
infarction with onset of symptoms in the preceding 12-24 hours. Patients had either persistent ST
elevation of 0.2 mV or more in two or more contiguous precordial leads, elevated cardiac
enzymes, and continuous typical chest pain for at least 30 minutes unrelieved by sublingual or IV
nitrates. Exclusion criteria consisted of studies previous acute MI, valvular or congenital heart
disease, cardiomyopathy, absence of sinus rhythm, LBBB, pregnant, severe comorbidities,
greater than 80 years of age, and patients unwilling or unable to give consent. The summary of
statistics reported or used were p values, RBI, ABI, and NNT.
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Table 1: Demographics and Characteristics of included studies
Study

Type

Singh6
(1996)

Randomized, 101
doubleblind,
placebo
controlled
trial

Colonna7
(2000)

Multicenter,
randomized,
double-blind
trial

Tarantini8
(2012)

	
  

# Pts

472

Age
(yrs)
Avg
4050s
y/o

Inclusion
criteria
Judge likely to
have AMI
with onset of
sxs in the
preceding 24
hrs

< 80 Seen at an
y/o
ICU within 24
h of having
their first
acute anterior
MI

Exclusion
criteria
Patients unable
or unwilling to
give consent,
Admitted more
than 24 hrs after
onset of sxs

W/D Interventi
on
0
oral LCarnitine
1.98g/d

Previous acute
MI, Valvular or
congenital heart
disease,
Cardiomyopathy,
Absence of sinus
rhythm, Left
bundle branch
block, Pregnant,
Concomitant
conditions that
could affect
follow-up, and
Participating in
another clinical
study
Randomized, 2,330 < 80 Continuous
Age >80 y/o,
1
doubley/o
typical CP for Valvular or
blind,
at least 30 min congenital heart
placebo
unrelieved by disease, HCM,
controlled
s.l. or IV
Severe renal or
trial
nitrates, Onset hepatic disorder,
of sxs of AMI comorbidity
within 12 h
limiting the pt’s
before
life expectancy,
randomization, Alcoholism,
and Persistent Pregnancy or
ST elevation
lactation, and
of 0.2 mV or
Unwillingness to
more in two or provide informed
more
consent
contiguous
precordial
leads

Carnitine
9g/d
continuou
s IV for
the first 5
days, then
PO 2g
TID for
next 12
months

Lcarnitine
9g/d by
continuou
s IV
infusion
for initial
5 days
then 4g/d
orally for
next 6
months
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OUTCOMES MEASURED

Outcomes measured in the Singh et al. study were: total cardiac events including death
and nonfatal infarctions, cardiac enzymes activity, infarct size, and complication were measured
by myocardial infarct size, levels of CK and CK-MB, electrocardiographic, complications at 28
days follow up that included deaths, LV function, arrhythmia, nonfatal re-infarction, and total
cardiac events.6 The Colonna et al. RCT study measured outcomes such as left ventricular
dilation, end diastolic volume, systolic volume, incidence of death of heart failure at 6 months,
infarct size, and residual stenosis that was measured by an Echocardiograph.7 The outcomes
measured by Tarantini et al. RCT study outcomes were combined occurrence of death and heart
failure that was measured by number of deaths at various times from randomization.8
RESULTS
The three randomized-controlled trials compared the efficacy of L-Carnitine to placebo in
preventing mortality in patients post myocardial infarction.
In the study by Singh et al, total cardiac events, which were defined as cardiac deaths and
nonfatal re-infarctions, were 15.6% in the L-carnitine group and 26.0% in the placebo group.
There was no significant decrease in cardiac deaths with treatment with L-carnitine vs. placebo
with p>0.05 and Confidence Limits (CL) (1.88, 0.22). There was a significant decrease in
nonfatal re-infarctions with L-carnitine vs placebo with p<0.05, Confidence Limits (CL) (1.86,
0.17). There was also a significant decrease in total cardiac events with L-carnitine vs placebo
with p<0.05 and Confidence Limits (CL) (1.62, 0.27). The treatment effects of L-carnitine on
mortality post MI are listed in Table 2. The relative risk reduction (RRR) is -0.4% and the
absolute risk reduction (ARR) is -10.4%. The numbers needed to treat (NNT) was -9. All data
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were analyzed on the basis of intention to treat and the outcome analyses were incorporated for
patients who were lost to follow up or died6.
Table 2: Treatment effects of L-carnitine treatment post AMI on cardiac events
CER

EER

RRR

ARR

NNT

0.26

0.156

-0.4

-0.104

-9

In the study by Taratini et al, at 6 months post MI the survival rate was not significantly
increased for L-carnitine group vs placebo group as determined by p=0.48. But at day 5 post MI,
the survival rate was significantly higher for the L-carnitine group vs placebo group with
p=0.041. The cumulative mortality rate at various times are as follows: at 0-5 days the
confidence interval (CI) was 0.37- 0.98 and p-value < 0.05; at 0-7 days the CI was 0.42- 1.05 and
p-value > 0.05; at 0-15 days the CI was 0.54- 1.26 and p-value > 0.05; at 0-30 days the CI was
0.53- 1.16 and p-value > 0.05; at 0-60 days the CI was 0.56- 1.18 and p-value > 0.05; at 0-90
days the CI was 0.60- 1.22 and p-value > 0.05; and at 0-180 days the CI was 0.63- 1.24 and pvalue > 0.05. The treatment effects of L-carnitine on mortality are listed in table 3. The relative
risk reduction (RRR) is -0.12% and absolute risk reduction (ARR) is -1.3%. The number needed
to treat (NNT) was -76. At 6 months, total of 142 patients out of 2,330 patients died. There were
67 patients that died the from the L-carnitine group which was a six-month mortality rate of
5.7% and the mortality rate of the placebo group was 6.5% at six-months that lead to a nonsignificant 12% reduction in mortality between L-carnitine and placebo (p=0.48). The
significant decreases in mortality were in the earlier periods of the study. At the five-day end
point, the mortality reduction was significant in the L-carnitine group of CI 0.37 and p-value=
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0.041. One patient assigned to the placebo group was loss to follow up and therefore was
excluded from all analyses and “worst-case” analysis was not done to those lost to follow up8.
Table 3: Reduction in mortality after MI with treatment with L-carnitine
CER

EER

RRR

ARR

NNT

P-value

0.105

0.09.2

-0.12

-0.013

-76

0.041

The study by Colonna et al, measures death rates between patients treated with Lcarnitine vs. placebo during hospitalization and from discharge to 1 year follow up. During
hospitalization 11 (4.7%) patients treated with L-carnitine died compared to 14 (5.9%) patients
treated with the placebo. Between discharge and 1 year follow up, 10 (4.3%) patients treated
with L-carnitine died compared to the placebo group where 13 (5.4%) patients died. The
treatment effects of L-carnitine on mortality reduction are listed in Table 4. The relative risk
reduction (RRR) is -0.2% and the absolute risk reduction (ARR) is -2.3%. The number needed to
treat (NNT) was -43. None of the participants in the study needed to discontinue the treatment.
“Worst-case” analysis was not done to those lost to follow up7.
Table 4: Mortality reduction post MI with treatment with L-carnitine
CER

EER

RRR

ARR

NNT

0.113

0.09

-0.2%

-0.023

-43

None of the participants were reported to have adverse events in the reviewed studies
from treatment with L-carnitine.
DISCUSSION
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This selective evidence based medicine review investigated three randomized controlled

trials to determine whether or not L-carnitine decreases mortality rates post myocardial
infarction. While the selected studies provided no definitive evidence that L-carnitine decreased
long-term mortality rates post myocardial infarction but these studies did suggest that L-carnitine
might be helpful with infarction size and early mortality rates.
In the Singh study et al, total cardiac mortality rates did not show a significant reduction
in the L-carnitine group compared to the placebo group (p>0.05) but did show a significant
reduction in cardiac events, which were defined as cardiac deaths and nonfatal re-infarctions. For
nonfatal re-infarctions with L-carnitine vs. placebo, there was a statistically significant decrease
(p<0.05). There was also a significant reduction in total cardiac events with L-carnitine
treatment, (p<0.05). The relative risk reduction (RRR) was -0.4%, so there was a 0.4% decrease
in adverse events with L-carnitine versus placebo. The absolute risk reduction (ARR) is -10.4%,
so there was a 10.4% decrease in adverse events with L-carnitine versus nothing. These values
are small and further demonstrate that L-carnitine is not much more effective than the placebo in
reducing mortality after an AMI. The authors of the article stated that carnitine may inhibit free
radical injury to the myocardium, so this can be protective for the myocardium and non-infarcted
areas. The study also suggests that there was a significant reduction in cardiac enzymes like
creatine kinase, creatine kinase-MB, and aspartate transaminase and a smaller increase in lactate
dehydrogenase, indicating less cardiac necrosis in the L-carnitine group. Decreasing necrotic
areas of myocardium is a major goal of treating AMI. Current methods (nitro, oxygen therapy,
CABG, stent) of trying to restore oxygenated blood flow are currently the gold standard but more
studies should be done to further evaluate the usefulness of L-carnitine. Limitations of the study
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may have been the samples size, comorbidities of the patients, and time sensitive drug therapy
after onset of MI could have impacted the outcome 6
In the study by Colonna et al, there seems to be minimal benefit to using L-carnitine.
The mortality rate during hospitalization was 4.7% when treated with L-carnitine compared to
5.9% when treated with the placebo. Also, the mortality rates after discharge to one year follow
up period were 4.3% for L-carnitine group compared to the placebo group at 5.4%. The RRR and
ARR were both small showing that L-carnitine is not much more effective than the placebo in
reducing mortality post MI. The study suggests that long-term L-carnitine treatment limits left
ventricular dilatation, which should help the patient to prevent future sequelae and even death
from the AMI. Limitations to the study could have been different facilities MI protocols,
patients’ comorbidities, and time sensitive drug therapy after onset of MI could have also
impacted the outcomes7.
The study by Taratini et al, showed the mortality rate at 6 months was 5.7% for the Lcarnitine group and 6.5% for the placebo group. This was a non-significant, 12% reduction in
long-term (baseline - 6 months) mortality (p=0.48) with L-carnitine vs. placebo. However, the
short-term (day 5) post MI survival rate was significant increased for the group treated with Lcarnitine group (p=0.041) as demonstrated by the cumulative mortality rate at 0-5 days. But as
stated in results portion, the cumulative mortality rate at 0-7 days, 0-15 days, 0-30 days, 0-60
days, 0-90 days, and 0-180 days all showed p-value > 0.05 demonstrating a non-significant
increase in those survival rates. RRR and ARR values were small and demonstrate that Lcarnitine is not much more effective than the placebo in reducing mortality after an AMI. The
NNT was 76 people to have a positive outcome. Limitations of the study could have been
comorbidities, and time sensitive drug therapy after onset of MI could have impacted the
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outcome. Another limitation is the study was conducted at different facilities that may have
different MI protocols. The study was terminated early due to the lower than expected
enrollment rate so the samples size could have been another limitation8.
All three studies show some evidence of the usefulness of L-carnitine. It does not
necessary decrease long-term mortality rates because some MIs may cause too much damage for
the individual patient to recover from the event. Most medical professionals would agree
decreasing infarcts sizes and cardiac enzymes, and preventing left ventricular dilatation will
improve the chances of survival and quality of life for the patients post MI. It is common
knowledge that “time is tissue” with cardiovascular events therefore, time to treatment and the
size of the area of infarction may have a role in determining the treatment effects of L-carnitine.
CONCLUSION
There is some evidence to suggest that L-carnitine may be effective in reducing mortality
short-term after an AMI but not long term. The studies reviewed demonstrated statistically
significant decreases in mortality only in the time frame directly following an AMI. Because of
these results, future studies on the effects of L-carnitine should be conducted focusing on its
efficacy short term after an AMI. The flaws in the conducted studies may have been that they
did not focus treatment on the short term, which is where L-carnitine appears to have the greatest
treatment effect.
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